ImmuCell Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio1.732.262.543.222.80
P/B Ratio1.671.581.551.901.52
Price/Tangible Book1.681.591.561.911.53
Price/OCF128.2364.9132.62
Enterprise Value Ratios
EV/Revenue2.173.102.753.223.13
EV/EBITDA39.6365.7822.7849.62
EV/EBIT240.62
Profitability & Returns
Return on Equity (ROE)-0.08%-0.21%-0.08%0.00%-0.04%
Return on Assets (ROA)-0.02%-0.07%-0.02%0.00%-0.02%
Return on Invested Capital (ROIC)-0.03%-0.13%-0.05%0.01%-0.05%
Return on Capital Employed (ROCE)-0.03%-0.13%-0.04%0.01%-0.04%
Leverage & Solvency Ratios
Debt/Equity0.550.670.410.320.38
Debt/EBITDA7.7512.963.579.69
Liquidity Ratios
Current Ratio3.412.734.556.425.50
Quick Ratio1.720.762.475.094.44
Efficiency Ratios
Asset Turnover0.600.390.420.450.39
Inventory Turnover2.431.892.264.093.68
Yield & Distribution Ratios
Earnings Yield-0.05%-0.15%-0.05%0.00%-0.02%
FCF Yield0.00%-0.17%-0.12%-0.03%-0.06%
Buyback Yield-0.05%0.00%-0.02%-0.05%-0.06%